BioCentury | Jan 25, 2020
Company News

Management tracks: Galapagos promotes Manto to CCO; plus Guardant, Horizon, Acceleron, Lilly, Krystal, Kura and more

...general manager, U.S. prescription business at Galderma Laboratories L.P. BioCentury Staff Guardant Health Inc. Krystal Biotech Inc. Roivant Sciences GmbH Ergomed plc Galapagos...
BioCentury | May 6, 2019
Distillery Therapeutics

ADORA2A identified as a thrombosis target

...as a pharmacologic stress agent for MPI. Swedish Orphan Biovitrum AB, CBT Development Ltd. and Ergomed plc...
BioCentury | Jul 3, 2018
Company News

Management tracks: Cigna, Novocure, Voyager

...succeed her as CMO. He was VP of Hansa Medical AB (SSE:HMED). Development services company Ergomed plc...
BioCentury | Feb 16, 2018
Clinical News

Ergomed's PeproStat meets in Phase II for intraoperative surgical bleeding

...In October, Ergomed plc (LSE:ERGO) reported top-line data from a Phase II trial to treat intraoperative surgical...
...sponges applied, dose applied and treatment failures. PeproStat is a peptide-based hemostat that binds fibrinogen. Ergomed plc...
...and ease of use, and safety Status: Phase II data Milestone: Start Phase III (2018) Claire Quang PeproStat Ergomed plc...
BioCentury | Dec 16, 2017
Company News

Management tracks: Chugai, bioMérieux

...Alexandre Mérieux will become to chairman and CEO. He succeeds Jean-Luc Bélingard. Development services company Ergomed plc...
...by CFO Stephen Stamp. The company also appointed Jan Petracek COO. Petracek is CEO of Ergomed’s...
BioCentury | Dec 15, 2017
Company News

Allergy, Ergomed in allergy deal

...Allergy Therapeutics plc (LSE:AGY) partnered with Ergomed plc (LSE:ERGO) to co-develop three of Allergy's OralVac subligual immunotherapy...
...basis, in which the physician obtains the therapy directly from the manufacturer before marketing authorization. Ergomed...
...country. Allergy Therapeutics plc (LSE:AGY), London, U.K. Ergomed plc (LSE:ERGO), Guildford, U.K. Business: Inflammation Chris Lieu Allergy Therapeutics plc Ergomed plc...
BioCentury | Oct 27, 2017
Clinical News

FDA lifts hold on Cel-Sci's Ph III trial of Multikine in SCCHN

...regional control, progression-free survival (PFS) and quality of life (QOL). Under an amended 2013 deal, Ergomed plc...
...cytokine mixture that includes interleukins, interferons, chemokines and colony-stimulating factors. Cel-Sci Corp. (NYSE-M:CVM), Vienna, Va. Ergomed plc...
...PFS) and quality of life (QOL) Status: Phase III resumed Milestone: NA Allison Johnson leukocyte interleukin injection Multikine Cel-Sci Corp. Ergomed plc...
BioCentury | Sep 1, 2017
Clinical News

Ergomed completes enrollment in Ph IIb of PeproStat

...control rate. Data are expected in 4Q17. PeproStat is a peptide-based hemostat that bind fibrinogen. Ergomed plc...
...surgical bleeding Endpoint: Bleed control rate Status: Phase IIb started Milestone: Phase IIb data (4Q17) Alicia Parker PeproStat Ergomed plc fibrinogen...
BioCentury | Jun 21, 2017
Company News

Management tracks

...Helén Tuvesson to CEO, effective July 1. She will succeed Tomas Leanderson. Development services company Ergomed plc...
BioCentury | May 19, 2017
Clinical News

Lorediplon meets in Phase II insomnia trial

...In February, Ergomed plc (LSE:ERGO) said 5 and 10 mg oral lorediplon each met the primary endpoint...
...receptor modulator. Grupo Ferrer Internacional S.A. (Barcelona, Spain) conducted the trial in collaboration with CRO Ergomed...
...in East Asia, including South Korea, China and Japan (see BioCentury, Feb. 10, 2014 ). Ergomed plc...
Items per page:
1 - 10 of 57
BioCentury | Jan 25, 2020
Company News

Management tracks: Galapagos promotes Manto to CCO; plus Guardant, Horizon, Acceleron, Lilly, Krystal, Kura and more

...general manager, U.S. prescription business at Galderma Laboratories L.P. BioCentury Staff Guardant Health Inc. Krystal Biotech Inc. Roivant Sciences GmbH Ergomed plc Galapagos...
BioCentury | May 6, 2019
Distillery Therapeutics

ADORA2A identified as a thrombosis target

...as a pharmacologic stress agent for MPI. Swedish Orphan Biovitrum AB, CBT Development Ltd. and Ergomed plc...
BioCentury | Jul 3, 2018
Company News

Management tracks: Cigna, Novocure, Voyager

...succeed her as CMO. He was VP of Hansa Medical AB (SSE:HMED). Development services company Ergomed plc...
BioCentury | Feb 16, 2018
Clinical News

Ergomed's PeproStat meets in Phase II for intraoperative surgical bleeding

...In October, Ergomed plc (LSE:ERGO) reported top-line data from a Phase II trial to treat intraoperative surgical...
...sponges applied, dose applied and treatment failures. PeproStat is a peptide-based hemostat that binds fibrinogen. Ergomed plc...
...and ease of use, and safety Status: Phase II data Milestone: Start Phase III (2018) Claire Quang PeproStat Ergomed plc...
BioCentury | Dec 16, 2017
Company News

Management tracks: Chugai, bioMérieux

...Alexandre Mérieux will become to chairman and CEO. He succeeds Jean-Luc Bélingard. Development services company Ergomed plc...
...by CFO Stephen Stamp. The company also appointed Jan Petracek COO. Petracek is CEO of Ergomed’s...
BioCentury | Dec 15, 2017
Company News

Allergy, Ergomed in allergy deal

...Allergy Therapeutics plc (LSE:AGY) partnered with Ergomed plc (LSE:ERGO) to co-develop three of Allergy's OralVac subligual immunotherapy...
...basis, in which the physician obtains the therapy directly from the manufacturer before marketing authorization. Ergomed...
...country. Allergy Therapeutics plc (LSE:AGY), London, U.K. Ergomed plc (LSE:ERGO), Guildford, U.K. Business: Inflammation Chris Lieu Allergy Therapeutics plc Ergomed plc...
BioCentury | Oct 27, 2017
Clinical News

FDA lifts hold on Cel-Sci's Ph III trial of Multikine in SCCHN

...regional control, progression-free survival (PFS) and quality of life (QOL). Under an amended 2013 deal, Ergomed plc...
...cytokine mixture that includes interleukins, interferons, chemokines and colony-stimulating factors. Cel-Sci Corp. (NYSE-M:CVM), Vienna, Va. Ergomed plc...
...PFS) and quality of life (QOL) Status: Phase III resumed Milestone: NA Allison Johnson leukocyte interleukin injection Multikine Cel-Sci Corp. Ergomed plc...
BioCentury | Sep 1, 2017
Clinical News

Ergomed completes enrollment in Ph IIb of PeproStat

...control rate. Data are expected in 4Q17. PeproStat is a peptide-based hemostat that bind fibrinogen. Ergomed plc...
...surgical bleeding Endpoint: Bleed control rate Status: Phase IIb started Milestone: Phase IIb data (4Q17) Alicia Parker PeproStat Ergomed plc fibrinogen...
BioCentury | Jun 21, 2017
Company News

Management tracks

...Helén Tuvesson to CEO, effective July 1. She will succeed Tomas Leanderson. Development services company Ergomed plc...
BioCentury | May 19, 2017
Clinical News

Lorediplon meets in Phase II insomnia trial

...In February, Ergomed plc (LSE:ERGO) said 5 and 10 mg oral lorediplon each met the primary endpoint...
...receptor modulator. Grupo Ferrer Internacional S.A. (Barcelona, Spain) conducted the trial in collaboration with CRO Ergomed...
...in East Asia, including South Korea, China and Japan (see BioCentury, Feb. 10, 2014 ). Ergomed plc...
Items per page:
1 - 10 of 57